<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027360</url>
  </required_header>
  <id_info>
    <org_study_id>S_04_06_21_5186</org_study_id>
    <nct_id>NCT05027360</nct_id>
  </id_info>
  <brief_title>Sodium NItroPrusside Treatment in Acute Heart Failure</brief_title>
  <acronym>SNIP-AHF</acronym>
  <official_title>Sodium NItroPrusside Treatment in Acute Heart Failure: Multicenter, Observational, Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niguarda Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Niguarda Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this multicentric observational retrospective study is to assess the&#xD;
      efficacy and safety of SNP as part of the treatment regimen of AHF patients and to identify&#xD;
      predictors of efficacy. The primary efficacy endpoint is brain natriuretic peptide (BNP) or&#xD;
      N-terminal pro b-type natriuretic peptide (NT-proBNP) reduction (at least 25% from baseline&#xD;
      levels) 48 hours after initiation of SNP infusion. AHF presentation (de novo or ADHF),&#xD;
      systolic blood pression at presentation, left ventricle ejection fraction and dimension,&#xD;
      entity of mitral regurgitation and central venous pressure will be evaluated in order to&#xD;
      identify predictors of efficacy of SNP (in terms of primary endpoint).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present is a multicenter, observational, retrospective study. All consecutive patients&#xD;
      admitted with a diagnosis of AHF to the Cardiothoracovascular Departments of the ASST Grande&#xD;
      Ospedale Metropolitano Niguarda (Milan), ASST Ospedale Papa Giovanni XXIII (Bergamo) and&#xD;
      Ospedale Le Molinette (Torino), and treated with intravenous SNP between January 2016 and&#xD;
      January 2020 will be included, and medical records screened. Through the collaboration of the&#xD;
      two joining institution, the investigator plan to include approximately 300 patients.&#xD;
      Inclusion criteria are: age 18 years or older; AHF diagnosis, defined as rapid onset or&#xD;
      worsening of symptoms and/or signs of HF; Intravenous SNP treatment. Exclusion criteria are:&#xD;
      Age &lt;18 years old; AHF after cardiac surgery; AHF complicated by cardiogenic shock requiring&#xD;
      high dosage (defined as inotropic score &gt;10) vasoactive agents and/or short-term&#xD;
      extracorporeal life support (i.e. VA-ECMO, Impella). Inotropic score (IS) calculated as:&#xD;
      dopamine dose (μg/kg/min) + dobutamine dose (μg/kg/min) + 100 × epinephrine dose (μg/kg/min)&#xD;
      + 100 × norepinephrine dose (μg/kg/min) + 10 × phosphodiesterase 3 inhibitor dose&#xD;
      (μg/kg/min). Invasive monitoring of central venous pressure (CVP) and arterial pressure may&#xD;
      be present. The Swan Ganz pulmonary artery catheter for continuous haemodynamic monitoring&#xD;
      will be rarely used. Simultaneous intravenous diuretics and concomitant inotropic agents with&#xD;
      a maximun IS&lt;20 administration will be tolerated. SNP will be administered intravenously by a&#xD;
      continuous infusion at a dose of 0.2 up to 2 mcg/kg/min. Titration of SNP up to the maximum&#xD;
      tolerated dose will be based on achieving decongestion, defined as decrease in CVP and&#xD;
      reduction of pulmonary congestion, with a target mean arterial pressure of 65 to 70 mmHg.&#xD;
      Headache or severe hypotension, as well as documented thiocyanate toxicity, will warrant&#xD;
      discontinuation of SNP therapy. The primary objective of our study is to assess the efficacy&#xD;
      and safety of SNP as part of the treatment regimen of AHF patients and to identify predictors&#xD;
      of efficacy. The primary efficacy endpoint is brain natriuretic peptide (BNP) or N-terminal&#xD;
      pro b-type natriuretic peptide (NT-proBNP) reduction (at least 25% from baseline levels) 48&#xD;
      hours after initiation of SNP infusion. Secondary endpoints include: Survival free from&#xD;
      rehospitalization for HF at 6 months; 30-day and 6-month mortality; Composite of long-term&#xD;
      LVAD implantation or HTx at 30 days and 6 months; Length of intensive care unit and total&#xD;
      hospital stay. Safety endpoints are: thiocyanate toxicity, headache, severe hypotension&#xD;
      requiring discontinuation of therapy, ventricular arrhythmias The investigators will evaluate&#xD;
      the following baseline patients' characteristics in order to identify predictors of efficacy&#xD;
      of SNP (in terms of primary endpoint): AHF presentation (de novo or ADHF); SBP at&#xD;
      presentation (preserved, i.e. 90-140 mmHg; elevated, i.e. &gt;140 mmHg; low, &lt;90 mmHg); left&#xD;
      ventricle ejection fraction (LVEF), graded as reduced (&lt;40%), mid-range (40-49%) or preserved&#xD;
      (≥50%); end-diastolic diameter (EDD); entity of mitral regurgitation (none/mild or&#xD;
      moderate/severe mitral regurgitation); CVP (&lt; 8 mmHg or ≥8 mmHg) Patient demographics,&#xD;
      haemodynamics, laboratory values, echocardiographic parameters, adverse events and clinical&#xD;
      outcomes will be obtained by complete chart review.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NT-pro-BNP or BNP reduction</measure>
    <time_frame>48 hours</time_frame>
    <description>Significant reduction (at least 25% from baseline levels) 48 hours after initiation of SNP infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>6 months</time_frame>
    <description>Survival free from re-hospitalizations for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days and 6 months</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart replacement therapies</measure>
    <time_frame>30 days and 6 months</time_frame>
    <description>Composite of long-term LVAD implantation or HTx</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Length of intensive care unit and total hospital stay</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Acute heart Failure AHF</arm_group_label>
    <description>AHF diagnosis, defined as rapid onset or worsening of symptoms and/or signs of HF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SNP - Sodium Nitroprusside</intervention_name>
    <description>The primary objective of our study is to assess the efficacy and safety of SNP as part of the treatment regimen of AHF patients and to identify predictors of efficacy.</description>
    <arm_group_label>Acute heart Failure AHF</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients admitted with a diagnosis of AHF to the Cardiothoracovascular&#xD;
        Departments of the ASST Grande Ospedale Metropolitano Niguarda (Milan), ASST Ospedale Papa&#xD;
        Giovanni XXIII (Bergamo) and Ospedale Le Molinette (Torino), and treated with intravenous&#xD;
        SNP between January 2016 and January 2020 will be included, and medical records screened.&#xD;
        Through the collaboration of the two joining institution, we plan to include approximately&#xD;
        300 patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  AHF diagnosis, defined as rapid onset or worsening of symptoms and/or signs of HF.&#xD;
             According to a recently proposed new definition, HF is a clinical syndrome with&#xD;
             current or prior Symptoms and or signs caused by a structural and/or functional&#xD;
             cardiac abnormality (as determined by EF &lt;50%, abnormal cardiac chamber enlargement,&#xD;
             E/E' &gt;15, moderate/severe ventricular hypertrophy or moderate/severe valvular&#xD;
             obstructive or regurgitant lesion) and corroborated by at least one of the following:&#xD;
             Elevated natriuretic peptide levels ; Objective evidence of cardiogenic pulmonary or&#xD;
             systemic congestion by diagnostic modalities such as imaging (e.g. by chest X-ray or&#xD;
             elevated filling pressures by echocardiography) or haemodynamic measurement (e.g.&#xD;
             right heart catheterization, pulmonary artery catheter) at rest or with provocation&#xD;
             (e.g. exercise).&#xD;
&#xD;
          -  Intravenous SNP treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years old&#xD;
&#xD;
          -  AHF after cardiac surgery&#xD;
&#xD;
          -  AHF complicated by cardiogenic shock requiring high dosage (defined as inotropic score&#xD;
             &gt;10) vasoactive agents and/or short-term extracorporeal life support (i.e. VA-ECMO,&#xD;
             Impella). Inotropic score (IS) calculated as: dopamine dose (μg/kg/min) + dobutamine&#xD;
             dose (μg/kg/min) + 100 × epinephrine dose (μg/kg/min) + 100 × norepinephrine dose&#xD;
             (μg/kg/min) + 10 × phosphodiesterase 3 inhibitor dose (μg/kg/min).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nuccia Morici, MD</last_name>
    <phone>+39026444</phone>
    <phone_ext>2565</phone_ext>
    <email>nuccia.morici@ospedaleniguarda.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Garatti, MD</last_name>
    <phone>+39026444</phone>
    <phone_ext>2565</phone_ext>
    <email>laura.garatti@ospedaleniguarda.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <state>Italia</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuccia Morici, MD</last_name>
      <phone>+39026444</phone>
      <phone_ext>2565</phone_ext>
      <email>nuccia.morici@ospedaleniguarda.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 28, 2021</last_update_submitted>
  <last_update_submitted_qc>August 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Heart Failure</keyword>
  <keyword>sodium nitroprusside</keyword>
  <keyword>NTproBNP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroprusside</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>not yet decided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

